Literature DB >> 3553247

Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.

H I Katz, N T Hien, S E Prawer, L I Mastbaum, J J Mooney, C R Samson.   

Abstract

Multiple clinical and laboratory evaluations, including morning plasma cortisol levels, were done in forty patients having moderate to severe psoriasis vulgaris prior to and during treatment with either betamethasone dipropionate in optimized vehicle or clobetasol-17-propionate ointment. The study was randomized, double-blind, and of parallel group design, lasting 3 weeks. Both drugs were effective (3 of 4 achieving at least 75% or more improvement). Temporary reversible suppression of the hypothalamic-pituitary-adrenal axis, as reflected by low morning plasma cortisol determinations, was found in eight of forty patients (20%). The clinician should respect the potential for superpotent topical steroids to cause laboratory evidence of adrenal suppression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3553247     DOI: 10.1016/s0190-9622(87)70105-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  Topical corticosteroids. Which drug and when?

Authors:  B Giannotti; N Pimpinelli
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

2.  Current treatment of psoriasis.

Authors:  J D Epstein
Journal:  Can Fam Physician       Date:  1987-10       Impact factor: 3.275

Review 3.  Topical therapies for psoriasis: evidence-based review.

Authors:  Tarek Afifi; Gillian de Gannes; Changzheng Huang; Youwen Zhou
Journal:  Can Fam Physician       Date:  2005-04       Impact factor: 3.275

4.  Longitudinal in vivo tracking of adverse effects following topical steroid treatment.

Authors:  Andrew J Bower; Zane Arp; Youbo Zhao; Joanne Li; Eric J Chaney; Marina Marjanovic; Angela Hughes-Earle; Stephen A Boppart
Journal:  Exp Dermatol       Date:  2016-02-13       Impact factor: 3.960

5.  Herbal creams used for atopic eczema in Birmingham, UK illegally contain potent corticosteroids.

Authors:  H M Ramsay; W Goddard; S Gill; C Moss
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

6.  Characterization of a novel non-steroidal glucocorticoid receptor agonist optimized for topical treatment.

Authors:  Stefan Eirefelt; Martin Stahlhut; Naila Svitacheva; Martin A Carnerup; Joel Mauricio Correa Da Rosa; David Adrian Ewald; Troels T Marstrand; Mikkel Krogh-Madsen; Georg Dünstl; Kevin Neil Dack; Anna Ollerstam; Hanne Norsgaard
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.